Eco Animal Health Gp - Share Awards to Executive Directors

ECO Animal Health

29/08/2025 07:00

RNS Number : 1368X

Eco Animal Health Group PLC

29 August 2025

 

29 August 2025

 

 

  

ECO Animal Health Group plc

("ECO" or the "Company")

 

Share Awards to Executive Directors

 ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announce that on 28 August 2025, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan ("LTIP") over 374,318 ordinary shares in the Company (representing approximately 0.55 percent of the Company's issued share capital) to the Executive Directors listed below.

 

Name
Position
Number of Share Awards
David Hallas
Chief Executive Officer
215,106
Chris Wilks
Chief Financial Officer
159,212

 

These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company's 2025 Annual Report which was published on 28 August 2025.

In addition, on 28 August 2025 nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 60,295 ordinary shares in the Company (representing approximately 0.09 percent of the Company's issued share capital) to the two Executive Directors listed below. These awards relate to the deferral of 33% of the annual bonus for Executive Directors earned in respect of the Company's financial year ended 31 March 2025.

 

Name
Position
Number of Deferred Share Options
David Hallas
Chief Executive Officer
35,472
Chris Wilks
Chief Financial Officer
24,823

 

As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors to be deferred in exchange for an award of nominal cost options which vest after 3 years and are subject to malice and clawback provisions.

 

-Ends-

For further information please contact:

ECO Animal Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
020 7496 3000
Investec (Joint Broker)
Gary Clarence
Lydia Zychowska
020 7597 5970
Equity Development
Hannah Crowe
Matt Evans
020 7065 2692
ICR Healthcare (Financial PR)
Mary-Jane Elliott
Jessica Hodgson
020 3709 5700
ecoanimalhealth@icrhealthcare.com


About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
David Hallas
2.
Reason for the notification
a.
Position/status
Chief Executive Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Eco Animal Health Group Plc
b.
LEI
2138009XN9DJ3YP70B55
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over ordinary shares of 5p each.
GB0032036807
b.
Nature of the transaction
1. Award of nominal cost conditional share awards under the Company's LTIP ("LTIP")
2. Nominal cost share awards under the Company's Deferred Bonus Plan ("DBS").
c.
Price(s) and volume(s)
Price(s)
Volume(s)
1.
LTIP
5p
215,106
2.
DBS
5p
35,472
d.
Aggregated information
Aggregated volume
Price
n/a
e.
Date of the transaction
28 August 2025
f.
Place of the transaction
Off Market

 

1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
Chris Wilks
2.
Reason for the notification
a.
Position/status
Chief Financial Officer
b.
Initial notification
/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Eco Animal Health Group Plc
b.
LEI
2138009XN9DJ3YP70B55
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type of instrument
Identification code
Options over ordinary shares of 5p each.
GB0032036807
b.
Nature of the transaction
1. Award of nominal cost conditional share awards under the Company's LTIP ("LTIP")
2. Nominal cost share awards under the Company's Deferred Bonus Plan ("DBS").
c.
Price(s) and volume(s)
Price(s)
Volume(s)
1.
LTIP
5p
159,212
2.
DBS
5p
24,823
d.
Aggregated information
Aggregated volume
Price
n/a
e.
Date of the transaction
28 August 2025
f.
Place of the transaction
Off Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBVLLLEVLLBBL